All News

Try on some new healthy habits without grappling with a daunting obscure health recommendation to eat more whole grains.

Nobody knows you like you know you, and don’t let anyone tell you different.

Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.

What stands in the way of patient-physician communications and how can we get around these barriers?

While new treatments continue to move into the realm of lung cancer treatment, surgery is still a mainstay, says Eric Lambright, M.D.

Recovering from breast cancer is a difficult time and can take the rest of your life, but it's important to fight for good health.

What do oncology nurses mean to their patients? This is an inside view from one grateful patient.

Experts from the Dana-Farber Cancer Institute discuss upcoming advances in the field of brain cancer treatment and research.

Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.

Looking back on the hardest of conversations during cancer treatments

Listening and small gestures can make a difference when someone you know is dealing with cancer.

A male breast cancer survivor discovers this path to tranquility.

Zykadia was granted FDA approval for the treatment of some patients with non-small cell lung cancer.

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

Edward Messing, M.D., discusses his recent paper which explored a possible way to reduce recurrence in some patients with bladder cancer.

Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.

Many chemo drugs are ototoxic which means they can cause hearing loss. This provides information on some of the drugs and resoruces which can help the chemo patient.

Trump proposed budget cuts to National Institutes of Health, National Cancer Institute and Medicaid

In the midst of the uncertainties of metastatic cancer, plans for treatment are the easy part. How to plan for life? That's more difficult.

Kari B. Wisinski, M.D., talks about new agents being explored in triple-negative breast cancer.

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.

The Oncologic Drugs Advisory Committee (ODAC) recommended the approval of Nerlynx (neratinib) for some patients with breast cancer.

While other cancers seem to occur more frequently in people with high blood sugar, that is not the case for brain cancer, according to a recent study.

Though deemed "safer" than normal cigarettes, electronic cigarettes may still pose a risk for bladder cancer.

No man is an island, but sometimes our interdependency isn’t clear.

Keytruda (pembrolizumab) was granted an accelerated approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients who have unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.

Early results for a new agent, pyrotinib (HTI-1001), are showing promise for the treatment of HER2-positive breast cancer, according to phase 1 results from China published in the Journal of Clinical Oncology, which showed that the drug was well-tolerated and showed anti-tumor activity.

Amye J. Tevaarwerk, M.D., discusses which patients with ER-positive breast cancer may be good candidates to continue endocrine therapy after five years.